Revance Therapeutics Inc. (RVNC)
3.65
0.00 (0.00%)
At close: Feb 05, 2025, 3:59 PM
No 1D chart data available
| Bid | 3.65 |
| Market Cap | 381.02M |
| Revenue (ttm) | 247.42M |
| Net Income (ttm) | -181.75M |
| EPS (ttm) | -3.34 |
| PE Ratio (ttm) | -1.09 |
| Forward PE | -3.62 |
| Analyst | n/a |
| Ask | 3.66 |
| Volume | 0 |
| Avg. Volume (20D) | 2,958,312 |
| Open | 3.65 |
| Previous Close | 3.65 |
| Day's Range | 3.65 - 3.65 |
| 52-Week Range | 2.30 - 7.56 |
| Beta | 0.95 |
About RVNC
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to tre...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 6, 2014
Employees 597
Stock Exchange NASDAQ
Ticker Symbol RVNC
Website https://www.revance.com
Next Earnings Release
Revance Therapeutics Inc. is scheduled to release its earnings on Feb 26, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+12.3%
Revance Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
2 months ago
-20.68%
Revance shares are trading lower after the company announced an amended and restated merger agreement with Crown Laboratories, under which Crown will commence a tender offer to acquire all outstanding shares of Revance's common stock for $3.10 per share in cash.
3 weeks ago · accessnewswire.com
March 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNCNEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal s...
